Colchicine (Tropolone Alkaloid · Pharmaceutical Gout Treatment · Informational Reference)
| Compound | Colchicine |
| Chemical class | Alkaloid — Protoalkaloid / Tropolone alkaloid |
| CAS | 64-86-8 |
| Primary source | Colchicum autumnale (autumn crocus / meadow saffron), Gloriosa superba (glory lily) |
| Key applications | Pharmaceutical for gout (acute), pericarditis, FMF; microtubule-binding; informational reference |
| Claim strength | High (as pharmaceutical) / Not applicable as supplement |
| Typical form | Pharmaceutical tablet (0.5–0.6 mg); not available as dietary supplement |
| Buy from Herbuno | Browse HerbIQ Compound Index → |
Name origin: From Colchis (an ancient kingdom on the eastern Black Sea coast, in modern Georgia), the region of origin of Colchicum autumnale. Colchicine has been used medicinally since at least 550 CE (documented in the Byzantine physician Alexander of Tralles for gout). It is one of the oldest known pharmaceutical compounds still in clinical use. Traditional use: Colchicum preparations (as tinctures of autumn crocus corms) were used in European and Arab traditional medicine for gout as early as the 6th century. However, the therapeutic dose and the toxic dose of colchicine are dangerously close — traditional colchicine preparations caused significant toxicity until pharmaceutical standardisation established precise dosing. Pharmaceutical status: Colchicine is FDA-approved (Colcrys®, Mitigare®) for: acute gout flare treatment, gout prophylaxis, and familial Mediterranean fever (FMF). A 2024 landmark RCT (COPE-AF) demonstrated colchicine reduces major cardiovascular events in patients with coronary artery disease (0.5 mg/day). Colchicine is a prescription pharmaceutical in the US, EU, UK, and most regulated markets. It is not available as a dietary supplement due to narrow therapeutic index and serious toxicity risk. Supplement status: Colchicine is a controlled pharmaceutical drug, not a supplement ingredient. Colchicum or glory lily (Gloriosa superba) herbal preparations are not appropriate for supplement use due to colchicine toxicity risk.
Colchicine — Pharmaceutical Mechanism and Applications
Mechanism — tubulin binding and neutrophil inhibition: Colchicine binds β-tubulin at the colchicine binding site (distinct from the taxol site), preventing microtubule polymerisation. In gout, the primary therapeutic mechanism is not tubulin binding per se but rather inhibition of NLRP3 inflammasome activation in neutrophils, preventing neutrophil recruitment to the urate crystal-laden joint. This anti-inflammatory mechanism (NLRP3/IL-1β pathway blockade) also underlies colchicine’s emerging cardiovascular applications. Pharmaceutical approval: FDA-approved for gout, FMF, pericarditis, and cardiovascular risk reduction.
Acute gout: Colchicine 1.2 mg followed by 0.6 mg one hour later is the evidence-based acute gout treatment — superior to high-dose colchicine (which caused GI toxicity without improved efficacy). Multiple RCTs and decades of clinical use confirm rapid, effective pain relief in acute gout. Claim strength: High (pharmaceutical evidence).
Cardiovascular — COPE-AF and COLCOT trials: The COLCOT RCT (n=4,745, 2019) showed colchicine 0.5 mg/day significantly reduced major adverse cardiovascular events in post-MI patients. The LoDoCo2 trial confirmed benefit in chronic coronary disease. This positions colchicine as an anti-inflammatory cardiovascular agent — a novel mechanism distinct from statins and antiplatelet agents. These are pharmaceutical RCTs, not supplement applications. Pharmaceutical evidence: High.
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Frequently Asked Questions — Colchicine
Why is colchicine so toxic at slightly higher doses?
Colchicine inhibits microtubule polymerisation — a process essential for cell division (mitosis requires intact microtubules for spindle formation) and many other cellular functions. At therapeutic doses (0.5–1.2 mg), the primary effect is anti-inflammatory via neutrophil inhibition. At higher doses, widespread microtubule disruption in rapidly dividing cells (GI epithelium, bone marrow, hair follicles) causes dose-dependent toxicity: GI (nausea, vomiting, diarrhoea), bone marrow suppression, alopecia, and in severe cases, multi-organ failure. The narrow therapeutic index requires pharmaceutical-grade dose precision.
Is meadow saffron (Colchicum) the same as saffron (Crocus)?
No — Colchicum autumnale (meadow saffron, autumn crocus) is a completely different plant from Crocus sativus (true saffron). They are both bulbous plants with similar-looking flowers but are unrelated botanically. True saffron (Crocus sativus) contains no colchicine and is safe as a culinary and supplement ingredient. Meadow saffron (Colchicum) contains colchicine throughout all plant parts — ingesting any part of Colchicum plant is potentially lethal. The name confusion has caused poisoning cases when people collected Colchicum thinking it was wild garlic or wild onion (which it also superficially resembles).
Can any botanical supplement provide colchicine-like gout relief?
No supplement ingredient reproduces colchicine’s specific NLRP3/IL-1β anti-inflammatory mechanism for acute gout with equivalent efficacy. However, some botanical compounds have documented uric acid-lowering or anti-inflammatory effects relevant to gout management: quercetin (inhibits xanthine oxidase, reducing uric acid synthesis), cherry/anthocyanins (reduce uric acid and CRP, multiple human studies), and celery seed extracts (3nB phthalide reduces uric acid). None approach pharmaceutical colchicine efficacy for acute gout treatment.
What is Gloriosa superba and does it contain colchicine?
Gloriosa superba (glory lily, flame lily) is a tropical plant used in traditional African and Asian medicine, particularly in Sri Lankan and Indian traditional use. All parts of the plant (seeds, tubers, leaves) contain colchicine and related alkaloids. Gloriosa is highly toxic — ingestion has caused deaths in India and Sri Lanka, including cases of deliberate poisoning. It is not suitable for herbal supplement preparations. Like Colchicum, Gloriosa preparations represent a traditional colchicine use context that should not be reproduced in modern supplement formulation.
Related compounds: Amygdalin, Taxol, Vasicinone, Capsaicin
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery